Skip to main content

BRIEF RESEARCH REPORT article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1463026
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 14 articles

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

Provisionally accepted
Zhuoling Zheng Zhuoling Zheng 1Yihong Zhao Yihong Zhao 2Jingwen Xie Jingwen Xie 1Min Gao Min Gao 1Yiting Wang Yiting Wang 1Xiaoyan Li Xiaoyan Li 1*
  • 1 The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • 2 School of Pharmaceuticals Sciences (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China

The final, formatted version of the article will be published soon.

    Introduction: Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumabinduced blood pressure (BP) elevation. This study aims to identify clinical risk factors associated with bevacizumab-related hypertension in patients with mCRC. Methods: This retrospective study included 178 patients treated between January and June 2020. Demographic data and medical histories were extracted from hospital electronic medical records. Results: Among the 178 patients, 54 (30.3%) developed bevacizumab-related hypertension, with a median onset time of 48 days. Univariate and multivariate analyses identified pre-existing hypertension (odds ratio [OR], 3.30; 95% confidence interval [CI], 1.56-6.99) and age ≥60 years (OR, 2.04; 95% CI, 1.00-4.17) as independent risk factors for bevacizumab-related hypertension. The area under the receiver operating characteristic (ROC) curve was 0.66 (95% CI, 0.57-0.75, P < 0.001). The median overall survival (OS) for the cohort was 30.53 months (95% CI,. No significant differences in OS were observed between patients with and without bevacizumab-related hypertension (31.13 vs. 27.87 months, P = 0.86). Conclusions: Pre-existing hypertension and age ≥60 years are significant clinical risk factors for bevacizumab-related hypertension in mCRC patients. Bevacizumab-related hypertension did not affect overall survival. Clinicians should closely monitor BP within the first two months of bevacizumab treatment in high-risk patients.

    Keywords: bevacizumab, Hypertension, Risk factors, colorectal cancer, adverse effect

    Received: 11 Jul 2024; Accepted: 14 Oct 2024.

    Copyright: © 2024 Zheng, Zhao, Xie, Gao, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xiaoyan Li, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.